此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic Cosmos

2026年11月17日 更新者:Pfizer

REAL-WORLD EFFECTIVENESS OF RSV VACCINES AMONG ADULTS USING TARGET TRIAL EMULATION IN EPIC COSMOS

Among non-pregnant adults observed in Epic Cosmos since August 2023 who are eligible for RSV vaccination, what is the effectiveness of ABRYSVO® (RSVpreF), compared with unvaccinated individuals, in preventing RSV-related and all-cause acute respiratory illness (ARI), lower respiratory tract disease (LRTD), and other outcomes of interest, within a target trial emulation (TTE) framework

研究概览

地位

主动,不招人

研究类型

观察性的

注册 (估计的)

293334

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • New York
      • New York、New York、美国、10001
        • Pfizer

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

概率样本

研究人群

The study population will include non-pregnant adults aged ≥18 years and ≥ 60 years in the United States with care observed in Epic Cosmos, contributing healthcare systems on or after August 2023. Individuals will be required to have sufficient healthcare engagement to ensure adequate data capture and observability within the database. Within this population, vaccinated individuals will be identified by documented administration of an RSV vaccine in structured EHR data.

描述

Inclusion:

Vaccinated Cohort

Patients must meet all the following inclusion criteria to be eligible for inclusion in the study:

  1. Adults meet the age criteria at the index date.
  2. Non-pregnant at the index date.
  3. Have at least one clinical encounter recorded in Epic Cosmos database during the 12 months prior to the index date.
  4. Have a documented administration of ABRYSVO® (or AREXVY®,mRESVIA® in the later phase) in Epic Cosmos on or after August 2023.

The index date for vaccinated individuals will be defined as the date of RSV vaccination.

Unvaccinated Cohort

Patients must meet all the following inclusion criteria to be eligible for inclusion in the study (in unvaccinated cohort):

  1. Adults meet the age criteria at the index date.
  2. Non-pregnant at the index date.
  3. Have at least one clinical encounter recorded in Epic Cosmos database during the 12 months prior to the index date.
  4. Have no documented receipt of any RSV vaccine in Epic Cosmos on or prior to the trial start date.

The index date for unvaccinated individuals will be defined as the start date of each sequential trial ('e.g.', 1st date of each month) in which they met eligibility criteria

Exclusion:

Exclusion Criteria Vaccinated Cohort

Patients meeting any of the following criteria will not be included in the study:

  1. Individual with receipt of any RSV vaccine in Epic Cosmos prior to the trial start date, as defined above (applicable to all analyses except for the analysis of recipients of multiple doses).
  2. Non-US residents. Unvaccinated Cohort

Patients meeting any of the following criteria will not be included in the study (in unvaccinated cohort):

  1. Individual with receipt of any RSV vaccine in Epic Cosmos on or prior to the trial start date, as defined above.
  2. Non-US residents. Patients must meet all the inclusion criteria and none of the exclusion criteria to meet eligibility requirements

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:RETROSPECTIVE

队列和干预

团体/队列
Vaccinated group

Individuals with documented receipt of an RSV vaccine in EHR data. Vaccines included: ABRYSVO® (Pfizer),AREXVY® (GSK), mRESVIA® (Moderna)

Unvaccinated comparator group:

Individuals not yet vaccinated at cohort entry, but otherwise eligible

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Incidence of RSV-related Acute Respiratory Infection (ARI) hospitalization
大体时间:up to 3 years
up to 3 years
Incidence of RSV-related Lower Respiratory Tract Disease (LRTD) hospitalization
大体时间:up to 3 years
up to 3 years

次要结果测量

结果测量
措施说明
大体时间
Incidence of RSV-related outcomes
大体时间:up to 3 years

ARI/LRTD non-inpatient encounter, ARI/LRTD severe outcome, ARI/LRTD critical outcome, CV events with different care settings, thromboembolic event with different care settings, asthma exacerbation with different care settings, COPD exacerbation with different care settings, Immunocompromised status and pneumonia with different care settings.

up to 3 years
Incidence of All-cause outcomes
大体时间:up to 3 years

all-cause ARI/LRTD encounter with different care settings, severe outcome, critical outcome, CV events with different care settings, thromboembolic event with different care settings, asthma exacerbation with different care settings, COPD exacerbation with different care settings, pneumonia with different care settings, Immunocompromised status and dementia (new onset).

up to 3 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

合作者

调查人员

  • 研究主任:Pfizer CT.gov Call Center、Pfizer

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月22日

初级完成 (估计的)

2027年1月31日

研究完成 (估计的)

2027年1月31日

研究注册日期

首次提交

2026年6月22日

首先提交符合 QC 标准的

2026年6月22日

首次发布 (实际的)

2026年6月29日

研究记录更新

最后更新发布 (实际的)

2026年11月20日

上次提交的符合 QC 标准的更新

2026年11月17日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • C3671094

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅